“We are extremely pleased to expand the Xylogenics board of directors and welcome these three new members with diverse experiences and backgrounds," says Butch Mercer, Chairman of Xylogenics.
Indianapolis (PRWEB) June 17, 2010
Indianapolis-based Xylogenics has named three new members to its board of directors. New members include William E. Parry, Joseph J. Prochaska, Jr., and Anthony J. Hubbard. Xylogenics is a bioengineering firm based in Indianapolis that develops genetically modified yeast strains to increase the production efficiency of ethanol from biomass.
William Parry, attorney and owner of Parry & Associates, a private legal practice, has extensive expertise in patent law and mergers and acquisitions, has been practicing law for more than 30 years. Parry of Hinsdale, Ill., served as vice president, general counsel, for Nalco Chemical Company from 1995 to 2000, and was president of Nalco Industrial Outsourcing from 2000-2001. Prior to joining Nalco Chemical, Parry worked for UOP, a Honeywell company involved in petroleum refining, gas processing, petrochemical production and major manufacturing industries, where he held the positions of director of business development and planning, Products Group, and director of Performance Chemicals, and assistant general counsel. Parry earned his J.D. from Duquesne University School of Law, and his B.A. and B.S. in Chemical Engineering from the University of Notre Dame. He is registered to practice law before the U.S. Patent and Trademark Office and in the states of Illinois and Pennsylvania.
Joseph Prochaska, Jr., brings extensive board experience to Xylogenics, having served on internal regulatory boards for more than 25 years and on private and non-profit boards for more than 12 years. Prochaska, of Northfield, IL, has held executive level positions in a number of organizations, including executive vice president and chief accounting officer for MetLife, Inc.; president, Aon Financial Services Group, Inc., and senior vice president and controller for Aon Corporation; and served as chairman and chief executive officer, and senior vice president and chief financial officer for Shand, Morahan & Co, Inc. and Evanston Insurance Company. Prochaska is qualified financial expert under Sarbanes-Oxley and has experience with global information technology and financial systems. Prochaska currently serves on the boards of Baird & Warner, Inc., and the Audit Committee and Advisory Council of the Hesburgh Libraries at the University of Notre Dame. Prochaska is a Certified Public Accountant and licensed insurance broker and is a member of the American Institute of Certified Public Accountants, National Association of Corporate Directors, Financial Executive Institute and World Presidents Organization. He has a BBA in Accounting from the University of Notre Dame.
Anthony Hubbard, a financial advisor and general manager for Stanbio Life Sciences has more than 15 years experience in management, operations and business development in emerging technology related to ventures. Hubbard, a resident of Indianapolis, has served in an executive capacity as vice president of finance, chief financial officer, and CEO for a number of firms, including a small business consulting firm, and biotechnology ventures. He was also a partner in an Indianapolis CPA firm that provided business, management and tax advisory services to entrepreneurial enterprises; and has held positions with the U.S. Small Business Administration, Indiana University Medical Center and a Chicago-based medical instrument company. He has served on the board of directors for a medical device industry trade association and various community groups. Hubbard is a licensed CPA and has a B.A. degree in microbiology and biological sciences, as well as an MBA in finance from Indiana University Kelly School of Business.
“We are extremely pleased to expand our board of directors and welcome these three new members with diverse experiences and backgrounds. Their proven leadership skills and expertise in business management, finance, patent law, and risk management will provide valuable perspectives and support to our company in achieving our strategic objectives to develop and market our proprietary bioengineered yeast strains and exclusive cellulosic ethanol technology to ethanol production facilities,” said Butch Mercer, Chairman of Xylogenics.
Xylogenics is also pleased to announce that co-founders Josh W. Heyen, senior research scientist and board member for Xylogenics and Ross R. Conklin have earned doctorate degrees in biochemistry and molecular biology, from Indiana University. “This is a tremendous accomplishment and further enriches the depth of knowledge and expertise we have within Xylogenics,” adds Mercer.
Xylogenics is a bioengineering firm based in Indianapolis that develops genetically modified yeast strains to increase the production efficiency of ethanol from biomass. These proprietary yeast strains can potentially boost fermentation yields by 30 to 50 percent in cellulosic ethanol production facilities. Xylogenics patent pending technology increases the amount of cellulosic material converted to ethanol resulting from its proprietary bioengineered yeast strains optimizing yield efficiencies. For more information, visit http://www.xylogenics.com.